证券记录 · 已归档季度
DNLI
Denali Therapeutics Inc. · Healthcare · Biotechnology
12被追踪持有人
—Δ持有人
35.56M持有股份
$825.78M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +6 | 103.66M | $2.65B | +11 | −4 |
| Q1 2026 | 93 | +4 | 96.77M | $1.85B | +11 | −8 |
| Q4 2025 | 89 | 0 | 110.68M | $1.83B | +1 | — |
| Q3 2025 | 19 | 0 | 67.26M | $976.61M | — | −1 |
| Q2 2025 | 17 | +1 | 74.76M | $1.05B | +2 | −1 |
| Q1 2025 | 13 | +1 | 44.98M | $611.55M | +2 | −1 |
| Q4 2024 | 12 | -1 | 38.31M | $780.78M | — | −1 |
| Q3 2024 | 12 | 0 | 34.10M | $993.27M | +1 | −1 |
| Q2 2024 | 12 | — | 35.56M | $825.78M | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 13.76M | — | $319.59M | 0.2% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 9.82M | — | $228.11M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (被动) | 2.98M | — | $69.27M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Geode Capital Management ✦ (被动) | 2.98M | — | $69.27M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 2.42M | — | $56.17M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 2.26M | — | $52.37M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 2.26M | — | $52.37M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 1.22M | — | $28.30M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 1.05M | — | $24.45M | 0.1% | n/c | 1 | SEC ↗ |
| 19 | Norges Bank ✦ (被动) | 823.94K | — | $19.13M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Millennium Management ✦ | 619.93K | — | $14.39M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Fisher Asset Management ✦ | 478.11K | — | $11.10M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Two Sigma Investments ✦ | 94.87K | — | $2.20M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 29.72K | — | $690,122 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 265 持有人, 147.10M 股份, $2.60B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 11
Schuth Alexander O.
Officer · 2.86K 股 · $71,625
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 04
SC 13G/A — BAILLIE GIFFORD & CO
Jul 08
SC 13G/A — T. Rowe Price Investment Management…
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据